2024-512173-27-00招募中3 期
NIRVANA-Lung : PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumour sites in advanced Non-small cell lung cAncer
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 327
- 试验地点
- 37
- 主要终点
- The primary endpoint of this trial is overall survival (OS) defined as the time from randomization to the date of documented death from any cause or last follow-up. OS rate will be reported at 1 year.
研究概览
简要总结
To compare Overall Survival (OS) rate between anti-PD-1 and chemotherapy versus anti-PD-1 and chemotherapy + radiotherapy with report of 1 year-rate.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Patient must have signed a written informed consent form prior to any study specific procedures
- •Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 6 months after completing treatment/therapy
- •Patients affiliated to the social security system (or equivalent).
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.
- •Histologically or cytologically confirmed advanced (stage IIIB/IIIC/IV), squamous or non-squamous NSCLC
- •NSCLC patients eligible for treatment with pembrolizumab and chemotherapy according to the European Marketing Authorization: a. squamous: in combination with carboplatin and either paclitaxel or nab-paclitaxel ; b. non squamous with no EGFR or ALK positive mutations: in combination with pemetrexed and a platinum based chemotherapy
- •Patient ≥18 years of age.
- •ECOG performance status 0 – 1
- •Life expectancy >3 months
- •Measurable lesion as assessed by RECIST version 1.
- •Metastases and/or primary tumour eligible for 3 dimensional conventional radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) in terms of dose constraints at organ at risk (according to QUANTEC review)
- •Patients must have adequate organ function defined by the following laboratory results obtained within 14 days prior to the first study treatment: a. absolute neutrophil count of ≥1 500 /mm3, b. platelets ≥ 100 000/mm3, c. haemoglobin >9 g/dL (transfusions allowed), d. creatinine clearance >60 mL/min e. bilirubin ≤1.5 X ULN (unless Gilbert’s syndrome where 3 X ULN is permitted) f. serum ALT and AST ≤2.5 X ULN (unless documented liver metastasis where ≤5 X ULN is permitted) g. ALP ≤2.5 X ULN (unless documented bone or liver metastasis where ≤5X ULN is permitted). h. INR , PT, PTT ≤1.5 X ULN (unless the subject is receiving anticoagulant therapy)
排除标准
- •Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation.
- •Symptomatic interstitial lung disease
- •Systemic immunosuppression or systemic immunosuppressive medicinal products within 2 weeks prior to study entry.
- •Concomitant treatment with steroids > 10 mg.
- •Prior invasive malignancy within the past 2 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity, bladder or cervix)
- •Known Acquired Immune Deficiency Syndrome (AIDS) or severe uncontrolled co-morbidity
- •Known currently active infection including hepatitis B and hepatitis C
- •Patient who was administered a live, attenuated vaccine within 28 days prior to enrolment
- •Patient with any other disease or illness that requires hospitalisation or is incompatible with the study treatment are not eligible. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study
- •Patient who have taken any investigational medicinal product or have used an investigational device within 30 days of inclusion
- •Pregnant or breast feeding woman
- •Stage IIIB/IIIC NSCLC patient eligible to curative (thoracic radiotherapy or surgery) treatments in first line treatment.
- •Person deprived of their liberty or under protective custody or guardianship.
- •If pemetrexed: patient is unable or unwilling to take folic acid or vitamin B12 supplementation
- •Pre-existing peripheral neuropathy of a severity of grade ≥ 2 by NCI CTCAE v5.
- •Known hypersensitivity to one of the compounds or substances used in this protocol.
- •Major surgery within the 28 days before initiating study treatment
- •Prior therapy with T-cell costimulation or checkpoint-targeted agents
- •Clinical need of radiotherapy (e.g.: whole brain irradiation, painful metastasis, bleeding, compressive metastases)
- •Irradiation within 2 months before inclusion.
- •Leptomeningeal carcinomatosis, or metastases with indistinct borders making targeting not feasible
- •Patient with evidence of active (presence of symptoms or requiring steroid treatment) central nervous system (CNS) metastases and/or carcinomatous meningitis. Patient with brain metastasis can be included if asymptomatic and not requiring steroids
- •Metastases located within 3 cm of the previously irradiated structures (EQD2doses): a. Spinal cord previously irradiated to >40 Gy; b. Brachial plexus previously irradiated to >50 Gy; c. Small intestine, large intestine, or stomach previously irradiated to >45 Gy; d. Brainstem previously irradiated to >50 Gy; e. Lung previously irradiated with prior V20Gy >30%
- •Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized with hormonal substitution, psoriasis
结局指标
主要结局
The primary endpoint of this trial is overall survival (OS) defined as the time from randomization to the date of documented death from any cause or last follow-up. OS rate will be reported at 1 year.
The primary endpoint of this trial is overall survival (OS) defined as the time from randomization to the date of documented death from any cause or last follow-up. OS rate will be reported at 1 year.
次要结局
- Acute/ late toxicity will be assessed according to the flowchart and graded by CTCAE v5 (toxic death and serious adverse events)
- Tumour response is defined as the percentage of patients with a complete response (CR) or partial response (PR), according to RECIST 1.1 and iRECIST (centralized response evaluation).
- Overall survival (OS) is defined as the time from randomization to the date of documented death from any cause or last follow-up. OS rate will be reported at 2 years.
- Progression-free survival (PFS) or iPFS [Seymour, 2017] are defined as the time from randomization until documented disease progression (PD) according to RECIST 1.1 and iRECIST (centralized response evaluation for both arms), or death, or last follow-up for patient alive whichever occurs first. PFS rate will be reported at 1 year.
- Cancer specific survival (CSS) is defined as the time from randomization to documented death from cancer from the treatment. CSS rate will be reported at 1 year.
- Local and distant controls in irradiated patients are defined as the time from randomization to the first documented loco-regional event or distant event. Control rates will be reported at 6 months and 1 year
- Quality of life will be assessed using self-administered questionnaires (EORTC QLQ-C30) according to the flowchart.
研究者
Nourredine AIT RAHMOUNE
Scientific
Unicancer
研究点 (37)
Loading locations...
相似试验
招募中
2 期
Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients.2023-509490-23-00Institut Bergonie80
尚未招募
2 期
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast CancerNCT07256964Henan Cancer Hospital216
进行中（未招募）
3 期
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4NCT03774732UNICANCER327
进行中（未招募）
3 期
评估 IBI363 对比多西他赛在经含铂化疗及抗 PD-1/PD-L1 免疫治疗失败的局部晚期或转移性鳞状非小细胞肺癌患者中的有效性和安全性的随机、开放、多中心、III 期研究CTR20253956180
招募中
2 期
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors2023-507516-12-00Taiho Oncology Inc.15